Key terms
About INO
Inovio Pharmaceuticals, Inc. engages in the provision of designed DNA medicines to treat and protect people from infectious diseases, cancer, and diseases associated with human papillomavirus. Its product pipeline includes VGX-3100, INO-3107, INO-5410, INO-4800, and PENNVAX-GP. The company was founded by David B. Weiner on June 29, 1983 and is headquartered in Plymouth Meeting, PA.
Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
52-week range
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date
Key terms
Ad Feedback
Smart score
Latest INO news
Nov 18
7:50am ET
Inovio price target lowered to $15 from $33 at Oppenheimer
Nov 18
6:26am ET
Cautious Hold Recommendation on Inovio Pharmaceuticals Amid Financial Challenges and Competitive Pressures
Nov 18
6:25am ET
Inovio price target lowered to $5 from $12 at H.C. Wainwright
Nov 18
12:35am ET
Inovio Pharmaceuticals: Strategic Progress and Promising Pipeline Justify Buy Rating
Nov 15
6:47am ET
RBC Capital Sticks to Its Hold Rating for Inovio Pharmaceuticals (INO)
Nov 14
11:03pm ET
Inovio Pharmaceuticals Advances DNA Medicine Development
Nov 14
7:50pm ET
Closing Bell Movers: Applied Materials down 6% after earnings, guidance
Nov 14
4:11pm ET
Inovio reports Q3 EPS (89c), consensus ($1.13)
Nov 14
7:05am ET
Options Volatility and Implied Earnings Moves Today, November 14, 2024
Nov 13
8:05am ET
Inovio reports data from Phase 1/2 trial on INO-3107
Nov 11
7:00am ET
Options Volatility and Implied Earnings Moves This Week, November 11 – November 15, 2024
Oct 21
8:10am ET
Inovio’s INO-3107 shows efficacy in recurrent respiratory papillomatosis
INO Financials
Key terms
Ad Feedback
INO Forecasts
analyst rating
- buy
- hold
- sell
1-year stock price forecast
INO Competitors
$ Market cap
P/E ratio
$ Price
1d change
52-week range
